Skip to main content
. 2025 Jun 10;312(3):857–870. doi: 10.1007/s00404-025-08059-7
This study identifies thioredoxin-ineracting (TXNIP) as a potential biomarker for obesity-induced insulin resistance in PCOS patients, offering a novel target for early diagnosis and personalized metabolic interventions in clinical practice.